<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604251</url>
  </required_header>
  <id_info>
    <org_study_id>CL-K1002-P010</org_study_id>
    <nct_id>NCT02604251</nct_id>
  </id_info>
  <brief_title>Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds</brief_title>
  <official_title>A Prospective Randomized Clinical Study Evaluating the Safety and Efficacy of the KLOX BioPhotonic WoundGel System When Compared With Silicone Sheets in the Treatment of Surgical Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KLOX Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KLOX Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, prospective, controlled study in patients having bilateral&#xD;
      breast reduction. Objectives of the study are to evaluate the safety and efficacy of the KLOX&#xD;
      BioPhotonic WoundGel System compared with the ones of Silicone Sheets in the treatment of&#xD;
      surgical wounds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events, Serious Adverse Events and Device Incidents</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients with adverse events, serious adverse events and device incidents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by the patient and by the investigator via the POSAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancouver Scar Scale (VSS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by the investigator via the VSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as assessed by blinded experts panel</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by a blinded experts committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of wound management</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Patient's self-assessment of ease of wound management by a specific questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Surgical Wounds</condition>
  <arm_group>
    <arm_group_label>Treatment with KLOX BioPhotonic WoundGel System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with silicone sheets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second breast will be randomized to be treated with silicone sheets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KLOX BioPhotonic WoundGel System</intervention_name>
    <description>Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.</description>
    <arm_group_label>Treatment with KLOX BioPhotonic WoundGel System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silicone sheets</intervention_name>
    <description>Treatment of the surgical wounds with silicone sheets.</description>
    <arm_group_label>Treatment with silicone sheets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated written informed consent form&#xD;
&#xD;
          2. Female patients, aged between 18 and 75 years old&#xD;
&#xD;
          3. Good general health, stable weight, free of systemic diseases such as diabetes,&#xD;
             arthritis, HIV infection or genetic disorder that could influence the outcome of the&#xD;
             treatment&#xD;
&#xD;
          4. Fitzpatrick skin type I to IV&#xD;
&#xD;
          5. Patients scheduled to go through bilateral breast reduction and expected to have newly&#xD;
             formed post-surgery breast incisions of comparable length, located on comparable skin&#xD;
             area&#xD;
&#xD;
          6. Patients able to understand, willing and able to comply with all study requirements&#xD;
&#xD;
          7. Patients must either be incapable of reproduction, or taking acceptable measures to&#xD;
             prevent pregnancy and have a negative pregnancy test prior to participation in the&#xD;
             Study&#xD;
&#xD;
          8. Females of childbearing potential must not be lactating at Study Screening and agree&#xD;
             to use adequate contraceptive method during the Study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to understand the Study and its requirements or to give informed consent&#xD;
&#xD;
          2. Patient has participated in any other clinical study within 3 months prior to Study&#xD;
             Screening and throughout the Study duration&#xD;
&#xD;
          3. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that&#xD;
             might interfere with healing within the last three months prior to Study Screening and&#xD;
             throughout the Study duration&#xD;
&#xD;
          4. Current use of anticoagulants such as (but not limited to) warfarin, clopidogrel,&#xD;
             enoxaparin or high doses of aspirin (&gt; 162 mg daily)&#xD;
&#xD;
          5. Patient with current alcohol use or actively consuming drugs (addiction) as it may&#xD;
             interfere with patient's ability to comply with Study procedures&#xD;
&#xD;
          6. Female patient pregnant, nursing or planning to become pregnant within the next 18&#xD;
             months&#xD;
&#xD;
          7. Patient is a current smoker or has been smoking or using nicotine product(s) in the&#xD;
             last three months&#xD;
&#xD;
          8. Patient with known photosensitivity, taking drug(s) to treat photosensitivity, with&#xD;
             concurrent disease (such as porphyria) or drug(s) (such as methotrexate or&#xD;
             chloroquine) known to induce severe photosensitivity of the skin&#xD;
&#xD;
          9. Patients who are immunocompromised or taking immunosuppressive therapy&#xD;
&#xD;
         10. Any concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the Study investigational device&#xD;
&#xD;
         11. Patient has ongoing malignant disease of any type, active systemic, local skin&#xD;
             infection or disease, autoimmune disease or any significant chronic disease which, in&#xD;
             the opinion of the investigator, might interfere with the evaluation of the Study&#xD;
             objectives or would result in non-compliance with the Study protocol&#xD;
&#xD;
         12. Patients with known hypersensitivity to pain medications&#xD;
&#xD;
         13. Patients with severe elastosis&#xD;
&#xD;
         14. Patients with severe or cystic acne on the area(s) to be treated&#xD;
&#xD;
         15. Presence of a metal stent or implant in the area(s) to be treated&#xD;
&#xD;
         16. Patients with derma resurfacing procedures or non-invasive skin-tightening procedures&#xD;
             including medium/deep chemical peeling, microdermabrasion, laser therapy or&#xD;
             prescription level glycolic acid treatment to the treatment area(s) within three&#xD;
             months prior to Study Screening or during the Study&#xD;
&#xD;
         17. Patients anticipating the need for surgery or overnight hospitalization during the&#xD;
             course of the Study&#xD;
&#xD;
         18. Patients with history of keloids or hypertrophic scars&#xD;
&#xD;
         19. Patients anticipating sun tanning bed or excessive sun exposure during the Study&#xD;
             period&#xD;
&#xD;
         20. Patients with significant breast asymmetry that may result in asymmetrical operative&#xD;
             incisions being made on the left and right breasts&#xD;
&#xD;
         21. Patients with breast asymmetry that may result in different post-operative tensions on&#xD;
             the wounds of the left and right breasts&#xD;
&#xD;
         22. Patients having had surgery in the area to be incised within one year of Study&#xD;
             Screening&#xD;
&#xD;
         23. Patients with tattoos in the areas of incisions&#xD;
&#xD;
         24. Patients with incisions that are actively bleeding&#xD;
&#xD;
         25. Patients with history of irradiated breast(s) in the area(s) to be treated.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Victoria Park Medispa</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmount Aesthetic Surgery Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z2M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

